Bifogade filer
Kurs & Likviditet
Beskrivning
Land | Sverige |
---|---|
Lista | Spotlight |
Sektor | Hälsovård |
Industri | Bioteknik |
2023-06-30 12:57:01
- Immuno Oncology with PD1 inhibitors successful in NSCLC in combination with cisplatin.
- CHOSA's DRP has the potential to turn this combination into precision therapy.
CHOSA Oncology AB ("CHOSA") presents highlights from the American Society of Clinical Oncology (ASCO) in a video on the homepage.
Listen to CEO Peter Buhl Jensen's presentation here (https://www.chosaoncology.se/investerare/presentationer/)
Previously communicated abstract on LiPlaCis data presented at ASCO can be found here (https://www.chosaoncology.com/cision/EE91EDE18AF24E93/) .